LMI – LMT

Enrolling Now
Study Information

An open-label, non-randomized, multi-center pivotal Phase 3 study to evaluate the efficacy and safety of PET imaging with [18F]PI-2620 for the detection of tau deposition when compared to post-mortem histopathology

 

Inclusion Criteria

  •  Age: 50 and over
  •  Targets: Prognosis <12mo.
  •  AD MEDS: No amyloid or tau targeting therapies
  •  Clinical Trials: No amyloid or tau targeting studies unless proof of placebo can be provided.
  •  Study Partner: Required
  •  Mechanism of Action: Next-generation positron emitting radiopharmaceutical for specific and sensitive in vivo detection of tau protein aggregates in the brain.

Exclusion Criteria

  • Neurological Disease History: Structural brain lesions >2cm. Encephalopathy due to EtOH or end-stage liver disease
  • Cancer History: N/A
  • Geriatric Depression Scale: N/A
  • HIV, HepB or HepC: N/A
  • C-SSRS: N/A
  • Alcohol or Drug Abuse: N/A
Apply to Participate

If you are interested in participating in this study, please complete the following preliminary qualification form.

We will follow-up with you after we have received your submission.

"*" indicates required fields

Name*
I agree to Headlands Research's Privacy Policy.*
I agree to receive email and automated text messages. Msg & data rates may apply.*
Hidden
This field is for validation purposes and should be left unchanged.